Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Boston Sci Controls New Asthma Device Market With Acquisition

This article was originally published in The Gray Sheet

  • News

Executive Summary

Boston Scientific will spend up to $443.5 million to get its hands on the first interventional device to treat asthma and, in the process, hopes to lessen its reliance on a sluggish cardiovascular franchise

You may also be interested in...



International News In Brief

NICE guidance on wound healing device

International News In Brief

NICE guidance on wound healing device

Boston Scientific Lays Out Near-Term Growth Plan

Boston Scientific’s ongoing effort to reorganize and recharge its product pipeline and reduce manufacturing costs will restore higher revenue growth over the next few years, executives said during a Nov. 19 day-long investor presentation.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
In Vivo
Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs

More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

See All
UsernamePublicRestriction

Register

MT029417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By